NASDAQ : MREO
Mereo BioPharma Group plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 0.3018 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 48.19M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 46.23M |
| Enterprise Value | 17.14M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 159.69M |
| Shares Change (YoY) | +2.30% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 16.88% |
| Float | 125.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2,811.78 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 1.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.88 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -375.77 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -67.85% |
| Return on Assets (ROA) | -42.46% |
| Return on Invested Capital (ROIC) | -48.94% |
| Return on Capital Employed (ROCE) | -113.88% |
| Weighted Average Cost of Capital (WACC) | 5.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$720,487 |
| Employee Count | 39 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -84.92% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.33 |
| Relative Strength Index (RSI) | 43.21 |
| Average Volume (20 Days) | 821,374 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.23M |
| Short Previous Month | 2.68M |
| Short % of Shares Out | 2.49% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.93 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -1,000 |
| Operating Income | -33.07M |
| Pretax Income | -28.10M |
| Net Income | -28.10M |
| EBITDA | -32.42M |
| EBIT | -33.07M |
| Earnings Per Share (EPS) | -$0.14 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 30.12M |
| Total Debt | 1.03M |
| Net Cash | 29.09M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 28.65M |
| Book Value Per Share | 0.18 |
| Working Capital | 27.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 652,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.35M |
| FCF Per Share | -$0.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.30% |
| Shareholder Yield | -2.30% |
| Earnings Yield | -49.86% |
| FCF Yield | -54.83% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.97 |
| Price Target Difference | 580.48% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 162.41% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.08 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |